

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE MEDICINAL PRODUCT**

AZOPT 10 mg/ml eye drops, suspension

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Brinzolamide 10 mg/ml.

For excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Eye drops, suspension.

Azopt is a white to off-white suspension.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

AZOPT is indicated to decrease elevated intraocular pressure in:

- ocular hypertension
- open-angle glaucoma

as monotherapy in patients unresponsive to beta-blockers or in patients in whom beta-blockers are contra-indicated, or as adjunctive therapy to beta-blockers.

### **4.2 Posology and method of administration**

When used as monotherapy or adjunctive therapy, the dose is one drop of AZOPT in the conjunctival sac of the affected eye(s) twice daily. Some patients may have a better response with one drop three times a day.

Nasolacrimal occlusion or gently closing the eyelid after instillation is recommended. This may reduce the systemic absorption of medications administered via the ocular route and result in a decrease in systemic side effects.

When substituting another ophthalmic antiglaucoma agent with AZOPT, discontinue the other agent and start the following day with AZOPT.

If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.

Shake well before use. To prevent contamination of the dropper tip and suspension, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.

#### Use in elderly

No dosage alteration in elderly patients is necessary.

#### Use in children

The efficacy and safety of AZOPT in patients below the age of 18 have not been established and its use is not recommended in these patients. However, there is limited experience in children.

The safety and efficacy of AZOPT have been studied in a small number of paediatric patients less than 6 years of age (see also 4.4, 4.8 and 5.1).

#### Use in hepatic and renal impairment

AZOPT has not been studied in patients with hepatic impairment and is therefore not recommended in such patients.

AZOPT has not been studied in patients with severe renal impairment (creatinine clearance < 30 ml/min) or in patients with hyperchloraemic acidosis. Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZOPT is therefore contra-indicated in such patients (see also 4.3).

### **4.3 Contra-indications**

- Hypersensitivity to brinzolamide or any of the excipients.
- Known hypersensitivity to sulphonamides (see also 4.4).
- Severe renal impairment.
- Hyperchloraemic acidosis (see also 4.2).

### **4.4 Special warnings and special precautions for use**

AZOPT is a sulphonamide inhibitor of carbonic anhydrase and, although administered topically, is absorbed systemically. Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. Brinzolamide has not been studied in pre-term infants (less than 36 weeks gestational age) or those less than 1 week of age. Patients with significant renal tubular immaturity or abnormalities should only receive brinzolamide after careful consideration of the risk benefit balance because of the possible risk of metabolic acidosis. The same types of undesirable effects that are attributable to sulphonamides may occur with topical administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and AZOPT. The concomitant administration of AZOPT and oral carbonic anhydrase inhibitors has not been studied and is not recommended.

There is limited experience with AZOPT in the treatment of patients with pseudoexfoliative glaucoma or pigmentary glaucoma.

AZOPT was primarily evaluated in concomitant administration with timolol during adjunctive glaucoma therapy. Therefore, there are limited data regarding the administration of brinzolamide with other antiglaucomatous agents.

AZOPT has not been studied in patients with narrow-angle glaucoma.

The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count). Specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration and wearing contact lenses might increase the risk for the cornea. Likewise, in other cases of compromised corneas such as patients with diabetes mellitus, careful monitoring is recommended.

Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since AZOPT contains

benzalkonium chloride, close monitoring is required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.

AZOPT has not been studied in patients wearing contact lenses. AZOPT contains the preservative benzalkonium chloride which may cause eye irritation. Benzalkonium chloride may be absorbed by soft contact lenses and is known to discolour soft contact lenses. Therefore, patients must be instructed to wait 15 minutes after instillation of AZOPT before inserting contact lenses. AZOPT must not be administered while wearing contact lenses.

Potential rebound effects following cessation of treatment with AZOPT have not been studied; the IOP-lowering effect is expected to last for 5-7 days.

Oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/or physical coordination in elderly patients. AZOPT is absorbed systemically and therefore this may occur with topical administration.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Specific interaction studies with other medicinal products have not been performed with AZOPT. In clinical studies, AZOPT was used concomitantly with timolol ophthalmic preparations without evidence of adverse interactions. Association between AZOPT and miotics or adrenergic agonists has not been evaluated during adjunctive glaucoma therapy.

Association between AZOPT and antiglaucomatous agents other than beta-adrenergic blocking agents has not been evaluated during adjunctive glaucoma therapy.

AZOPT is a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically. Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. The potential for interactions must be considered in patients receiving AZOPT.

The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main), CYP2A6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as ketoconazole, itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of brinzolamide by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly. However, accumulation of brinzolamide is unlikely as renal elimination is the major route. Brinzolamide is not an inhibitor of cytochrome P-450 isozymes.

#### **4.6 Pregnancy and lactation**

##### Pregnancy

There are no adequate data from the use of brinzolamide in pregnant women. Studies in animals have shown reproductive toxicity (see 5.3). The potential risk for humans is unknown. AZOPT should not be used during pregnancy unless clearly necessary.

##### Nursing mothers

It is not known whether brinzolamide is excreted in human milk, however, this substance is excreted in rat milk. It is strongly recommended to avoid the use of AZOPT when breast-feeding.

## 4.7 Effects on ability to drive and use machines

Temporary blurred vision or other visual disturbances, may affect the ability to drive or use machines (see also 4.8 Undesirable effects). If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.

## 4.8 Undesirable effects

In clinical studies involving over 1500 patients treated with AZOPT as monotherapy or adjunctive therapy to timolol maleate 0.5%, the most frequently reported treatment-related adverse events were: dysgeusia (bitter or unusual taste, see description below) (5.3%) and temporary blurred vision upon instillation, lasting from a few seconds to a few minutes (4.8%) (see also 4.7 Effects on ability to drive and use machines).

The following undesirable effects definitely, probably, or possibly related to treatment were reported during the clinical trials with AZOPT. Their incidence was either common (1.0% to less than 10.0%; maximum observed actual incidence of 5.3%) or uncommon (0.1% to less than 1.0%).

### Infections and Infestations

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* bronchitis and pharyngitis.

### Psychiatric disorders

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* depression.

### Nervous System Disorders

*Common ( $\geq 1\%$  to  $< 10\%$ ):* dysgeusia and headache.

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* dizziness and paraesthesia.

### Eye Disorders

*Common ( $\geq 1\%$  to  $< 10\%$ ):* abnormal sensation in eye, eye irritation, ocular hyperaemia and vision blurred.

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* asthenopia, blepharitis, conjunctivitis, conjunctivitis allergic, corneal erosion, deposit eye, eye discharge, eye pain, eye pruritis, eyelid margin crusting, eyelids pruritus, keratitis, keratoconjunctivitis sicca, keratopathy, lacrimation increased, ocular discomfort, photopsia and punctate keratitis.

### Respiratory, Thoracic, and Mediastinal Disorders

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* cough, dyspnoea, epistaxis, pharyngolaryngeal pain, respiratory tract congestion, rhinorrhoea, sinus disorder and throat irritation.

### Gastrointestinal Disorders

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* dry mouth, dyspepsia, mouth haemorrhage and nausea.

### Skin and Subcutaneous Tissue Disorders

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* alopecia, dermatitis contact and rash.

### General Disorders and Administration Site Conditions

*Uncommon ( $\geq 0.1\%$  to  $< 1\%$ ):* chest pain.

Dysgeusia (bitter or unusual taste in the mouth following instillation) was the most frequently reported systemic undesirable effect associated with the use of AZOPT during clinical studies. It is likely caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal. Nasolacrimal occlusion or gently closing the eyelid after instillation may help reducing the incidence of this effect (see also 4.2 Posology and method of administration).

In a small short-term clinical trial, approximately 12.5% of paediatric patients were observed to experience drug related adverse effects, the majority of which were local, nonserious ocular effects such as ocular hyperaemia, ocular discomfort, ocular discharge, and tearing (see also 5.1).

AZOPT is a sulphonamide inhibitor of carbonic anhydrase with systemic absorption. Gastrointestinal, nervous system, haematological, renal and metabolic effects are generally associated with systemic carbonic anhydrase inhibitors. The same type of undesirable effects that are attributable to oral carbonic anhydrase inhibitors may occur with topical administration.

## **4.9 Overdose**

No case of overdose has been reported.

Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possible nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels must be monitored.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic Group: Antiglaucoma preparations and miotics, carbonic anhydrase inhibitors.

ATC code: S01EC

Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eye. Carbonic anhydrase catalyses the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid.

Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP) which is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brinzolamide, an inhibitor of carbonic anhydrase II (CA-II), the predominant iso-enzyme in the eye, with an *in vitro* IC<sub>50</sub> of 3.2 nM and a K<sub>i</sub> of 0.13 nM against CA-II.

A clinical trial was conducted with AZOPT in 32 paediatric patients less than 6 years of age, diagnosed with glaucoma or ocular hypertension. Some patients were naive to IOP therapy whilst others were on other IOP-lowering medication(s). Those who had been on previous IOP medication were not required to discontinue their IOP medication(s) until initiation of monotherapy with AZOPT. Among patients who were naive to IOP therapy (10 patients), the efficacy of AZOPT was similar to that seen previously in adults, with mean IOP reductions from baseline ranging up to 5 mmHg. Among patients who were on topical IOP-lowering medications (22 patients), mean IOP increased slightly from baseline in the AZOPT group.

## 5.2 Pharmacokinetic properties

Following topical ocular administration, brinzolamide is absorbed into the systemic circulation. Due to its high affinity for CA-II, brinzolamide distributes extensively into the RBCs and exhibits a long half-life in whole blood (mean of approximately 24 weeks). In humans, the metabolite N-desethylbrinzolamide is formed, which also binds to CA and accumulates in RBCs. This metabolite binds mainly to CA-I in the presence of brinzolamide. In plasma, both brinzolamide and N-desethylbrinzolamide concentrations are low and generally below assay quantitation limits (<7.5 ng/ml).

Binding to plasma proteins is not extensive (about 60%). Brinzolamide is eliminated primarily by renal excretion (approximately 60%). About 20% of the dose has been accounted for in urine as metabolite. Brinzolamide and N-desethyl-brinzolamide are the predominant components in the urine along with trace levels of the N-desmethoxypropyl and O-desmethyl metabolites.

In an oral pharmacokinetic study, healthy volunteers received 1 mg capsules of brinzolamide twice daily for up to 32 weeks and RBC CA activity was measured to assess the degree of systemic CA inhibition.

Brinzolamide saturation of RBC CA-II was achieved within 4 weeks (RBC concentrations of approximately 20  $\mu\text{M}$ ). N-Desethyl-brinzolamide accumulated in RBCs to steady state within 20-28 weeks reaching concentrations ranging from 6-30  $\mu\text{M}$ . The inhibition of total RBC CA activity at steady state was approximately 70-75%.

Subjects with moderate renal impairment (creatinine clearance of 30-60 ml/minute) were administered 1 mg of brinzolamide twice daily orally for up to 54 weeks. Brinzolamide RBC concentration ranged from about 20 to 40  $\mu\text{M}$  by week 4 of treatment. At steady-state, brinzolamide and its metabolite RBC concentrations ranged from 22.0 to 46.1 and 17.1 to 88.6  $\mu\text{M}$ , respectively.

N-desethyl-brinzolamide RBC concentrations increased and total RBC CA activity decreased with decreasing creatinine clearance but brinzolamide RBC concentrations and CA-II activity remained unchanged. In subjects with the highest degree of renal impairment inhibition of total CA activity was greater although it was inferior to 90% at steady-state.

In a topical ocular study, at steady-state, brinzolamide RBC concentrations were similar to those found in the oral study, but levels of N-desethyl-brinzolamide were lower. Carbonic anhydrase activity was approximately 40-70% of predose levels.

## 5.3 Preclinical safety data

Topical ocular administration of brinzolamide to rabbits for one to six months resulted in slight, statistically significant increases in corneal thickness when given at concentrations of 1%, 2% and 4%, four times a day; these changes were not observed in other species. Chronic administration of brinzolamide to rats at a dose level of 8 mg/kg/day (up to 250 times the recommended human ophthalmic dose) resulted in changes associated with the pharmacology of carbonic anhydrase inhibition (i.e., urine volume and electrolyte changes, slight differences in serum electrolytes).

A statistically significant increase in urinary bladder tumours was observed in female mice given brinzolamide 10 mg/kg/day (250 times the recommended human ophthalmic dose), orally, for 24 months. Dose-related proliferative changes in the urinary bladder were observed among female mice at 1, 3 and 10 mg/kg/day, and among males at 3 and 10 mg/kg/day. The elevated bladder tumour incidence, which was statistically significant, was primarily due to the increased incidence of a tumour considered unique to mice.

Developmental toxicity studies in rabbits with oral doses of brinzolamide of up to 6 mg/kg/day (125 times the recommended human ophthalmic dose) revealed no effect on foetal development despite significant maternal toxicity. Similar studies in rats resulted in slightly reduced ossification of

skull and sternebrae of foetuses of dams receiving brinzolamide at doses of 18 mg/kg/day (375 times the recommended human ophthalmic dose), but not 6 mg/kg/day. These findings occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased foetal weights. Dose-related decreases in foetal weights were observed in pups of dams receiving brinzolamide orally ranging from a slight decrease (about 5-6%) at 2 mg/kg/day to nearly 14% at 18 mg/kg/day.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Benzalkonium chloride,  
mannitol,  
carbomer 974P,  
tyloxapol,  
edetate disodium,  
sodium chloride,  
hydrochloric acid/sodium hydroxide (to adjust pH)  
purified water.

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf-life**

2 years

4 weeks after first opening.

### **6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions.

### **6.5 Nature and content of container**

5 and 10 ml opaque low density polyethylene bottles with polypropylene screw caps (droptainer).

The following pack sizes are available: outer cartons containing 1 x 5 ml, 3 x 5 ml and 1 x 10 ml bottles. Not all pack sizes may be marketed.

### **6.6 Instructions for use and handling**

No special requirements.



**7. MARKETING AUTHORISATION HOLDER**

Alcon Laboratories (UK) Ltd.  
Boundary Way  
Hemel Hempstead  
Herts HP2 7UD  
United Kingdom.

**8. MARKETING AUTHORISATION NUMBERS**

EU/1/00/129/001 – 3

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 9 March 2000  
Date of last renewal: 9 March 2005

**10. DATE OF REVISION OF THE TEXT**

## **ANNEX II**

- A. MANUFACTURING AUTHORISATION HOLDERS  
RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OF THE MARKETING AUTHORISATION**

**A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer responsible for batch release

S.A. Alcon-Couvreur N.V.,  
Rijksweg 14,  
B-2870 Puurs,  
Belgium.

or

Alcon Cusí, S.A.,  
Camil Fabra 58,  
08320 El Masnou,  
Barcelona,  
Spain.

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

**B. CONDITIONS OF THE MARKETING AUTHORISATION**

• **CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER**

Medicinal product subject to medical prescription

• **CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

Not Applicable

• **OTHER CONDITIONS**

PSURs to be submitted annually until the second Renewal application.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING**

**CARTON FOR SINGLE BOTTLE, 5 ml, 10 ml + CARTON FOR 3 x 5 ml BOTTLES**

**1. NAME OF THE MEDICINAL PRODUCT**

AZOPT 10 mg/ml eye drops, suspension

**2. STATEMENT OF ACTIVE SUBSTANCE**

Brinzolamide 10 mg/ml

**3. LIST OF EXCIPIENTS**

Benzalkonium chloride, mannitol, carbomer 974P, tyloxapol, edetate disodium, sodium chloride, hydrochloric acid/sodium hydroxide (to adjust pH) and purified water. Contains benzalkonium chloride. See leaflet for further information.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Eye drops, suspension;

5 ml

10 ml

3 x 5ml

**5. METHOD AND ROUTE OF ADMINISTRATION**

Ocular use. Read the package leaflet before use. Shake well before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP: xx/xxxx

Discard four weeks after first opening.

Opened:

Opened (1):

Opened (2):

Opened (3):

**9. SPECIAL STORAGE CONDITIONS****10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE****11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Alcon Laboratories (UK) Ltd.

Boundary Way

Hemel Hempstead

Herts, HP2 7UD

United Kingdom.

**12. MARKETING AUTHORISATION NUMBER**

EU/1/00/129/001 1 x 5 ml

EU/1/00/129/002 1 x 10 ml

EU/1/00/129/003 3 x 5 ml

**13. MANUFACTURER'S BATCH NUMBER**

Lot.: xxxxx

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

<b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE LABEL, 5 ml &amp; 10 ml</b>
--

<b>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b>
---

AZOPT 10 mg/ml eye drops, suspension.  
Brinzolamide 10 mg/ml. Ocular use.

<b>2. METHOD OF ADMINISTRATION</b>
------------------------------------

Read the package leaflet before use.  
Discard 4 weeks after first opening.  
Opened:

<b>3. EXPIRY DATE</b>
-----------------------

EXP: xx/xxxx

<b>4. BATCH NUMBER</b>
------------------------

Lot.: xxxxx

<b>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b>
--

5 ml  
10 ml



## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

AZOPT 10 mg/ml eye drops, suspension  
Brinzolamide

**Read all of this leaflet carefully** before you start using this medicine.

This medicine has been prescribed for you personally. You should not pass it on to other people. It may harm them even if they have the same illness as you.

**Keep this leaflet.** You may need to read it again. If you still have questions after reading it, please ask your doctor or your pharmacist.

**The active substance** is brinzolamide 10 mg/ml.

**Other ingredients:** benzalkonium chloride, carbomer 974P, edetate disodium, mannitol, purified water, sodium chloride, tyloxapol.

Tiny amounts of hydrochloric acid or sodium hydroxide are sometimes added to keep acidity levels (pH levels) normal.

**The marketing authorisation holder for AZOPT** is Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts., HP2 7UD, United Kingdom.

**The maker** of AZOPT is S.A. Alcon - Couvreur N.V., Rijksweg 14, B-2870 Puurs, Belgium or Alcon Cusí, S.A., Camil Fabra 58, 08320 El Masnou, Barcelona, Spain.

### 1. WHAT AZOPT DOES

**AZOPT eye drops are used to treat high pressure in the eye.** This pressure can lead to an illness called **glaucoma**.

**High pressure in the eye.** Your eyeballs contain a clear, watery liquid which feeds the inside of the eye. Liquid is always emptying out of the eye, and more liquid is always being produced. If the eye fills up faster than it empties, the pressure inside the eye builds up. If it gets too high it can damage your sight.

**AZOPT is one of a group of medicines** for glaucoma called carbonic anhydrase inhibitors. It works by cutting down the production of liquid, which lowers the pressure in the eye. It may be used on its own or with other drops called beta-blockers, which also reduce pressure.

AZOPT is a milky liquid (a suspension) supplied in a pack containing a 5 ml or a 10 ml plastic (droptainer) bottle with a screw cap, or in a pack containing three 5 ml plastic (droptainer) bottles with screw caps. Not all pack sizes may be marketed.

### 2. BEFORE YOU USE AZOPT

**Do not use AZOPT...**

- **if you have kidney problems.**
- **if you are allergic** to brinzolamide or any of the other ingredients.
- **if you are allergic to medicines called sulphonamides.** AZOPT may cause the same allergy.
- **if you have a condition called hyperchloraemic acidosis** (too much acidity in your blood).

Ask your doctor for advice.

### Take special care using AZOPT...

- **if you have liver problems.** Talk to your doctor.
- **if you have dry eyes or cornea problems.** Talk to your doctor.
- **if you wear soft contact lenses.** Don't use the drops with your lenses in. Wait 15 minutes after using the drops before putting your lenses back in to your eyes. A preservative in AZOPT (benzalkonium chloride) may cause eye irritation and is also known to discolour soft contact lenses.

AZOPT is not to be used by people under 18 of years of age unless advised by your doctor.

### Pregnant/breast-feeding women

**If you are pregnant, or might get pregnant,** talk to your doctor before you use AZOPT.

**If you are breast-feeding,** don't use AZOPT; it may get into your milk.

### Driving or using machines

You may find that your vision is blurred for a time just after you use AZOPT. Some people have found themselves sleepy or dizzy when taking AZOPT. Do not drive or use machines until this has worn off.

### AZOPT and other medicines

If you are taking another carbonic anhydrase inhibitor (acetazolamide or dorzolamide, see section 1 WHAT AZOPT DOES), talk to your doctor.

Please tell your doctor or pharmacist if you are taking (or recently took) any other medicines. Remember to mention also medicines that you bought without prescription, over the counter.

## 3. HOW TO USE AZOPT

### The usual dose

**1 drop in the eye or eyes, twice a day** – morning and night.

Use this much unless your doctor told you to do something different. Only use AZOPT in both eyes if your doctor told you to. Take it for as long as your doctor told you to.

**Only** use AZOPT for dropping in your eyes.

**Turn the page for more advice**

Now turn over>


## 3. HOW TO USE AZOPT (*continued*)



1

2

3



### *How much to use*

< see side 1

- Get the AZOPT bottle and a mirror
- Wash your hands
- Shake the bottle and twist off the cap

- Hold the bottle, pointing down, between your thumb and middle finger
- Tilt your head back. Pull down your eyelid with a clean finger, until there is a 'pocket' between the eyelid and your eye. The drop will go in here (picture 1)
- Bring the bottle tip close to the eye. Use the mirror if it helps
- **Don't touch your eye or eyelid, surrounding areas or other surfaces with the dropper.** It could infect the drops
- Gently press on the base of the bottle to release one drop of AZOPT at a time.
- **Don't squeeze the bottle:** it is designed so that a gentle press on the bottom is all that it needs (picture 2)
- After using AZOPT, press a finger to the corner of your eye, by the nose (picture 3). This helps to stop AZOPT getting into the rest of the body.
- If you take drops in both eyes, repeat the steps for your other eye.
- Put the bottle cap back on firmly immediately after use
- Use up one bottle before opening the next bottle.

**If a drop misses your eye,** try again.

**If you get too much in your eyes,** rinse it all out with warm water. Don't put in any more drops until it's time for your next regular dose.

**If you forget to use AZOPT,** use a single drop as soon as you remember, and then go back to your regular routine. **Do not** use a double dose to make up.

**If you are using other eye drops,** leave at least 5 minutes between putting in AZOPT and the other drops.

#### 4. POSSIBLE SIDE EFFECTS

**Some people who use AZOPT** may get side effects. They can be unpleasant, but most of them soon pass.

**You can usually carry on taking the drops,** unless the effects are serious. If you're worried, talk to a doctor or pharmacist.

#### **COMMON SIDE EFFECTS**

*One or more of these may affect up to 6 in every 100 people.*

**Effects in the eye:** Temporary blurred vision, burning or stinging feeling just after using the drops; feeling of something in your eye; red eyes.

**Effects in the body:** Bitter or sour taste; headaches.

#### **Uncommon side effects**

*May affect up to 1 in every 100 people*

**Effects in the eye:** Discharge, pain, itching; inflammation of or damage to the eyeball surface; inflammation or crusting on the eyelids; increased tear production; tired or dry eyes; abnormal vision; flashes of light; deposit on the surface of the eye.

**Effects in the body:** Upset stomach, feeling sick, heartburn; breathlessness, chest pains, bronchitis; dry mouth, sore throat, nasal or sinus problems including runny nose or nose bleeds; bleeding in mouth; numbness or tingling sensation in fingers and toes; depression, dizziness; losing hair; skin irritation, rash, cough.

**If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist**

#### **5. KEEPING AZOPT**

This medicinal product does not require any special storage conditions.

**You must throw away a bottle four weeks after you first opened it**, to prevent infections. Write down the date you opened each bottle in the space below and in the space on the bottle label and box. For a pack containing a single bottle, write only one date.

Opened (1):

Opened (2):

Opened (3):

**Keep the drops in a safe place** where children can't see or reach them.

Don't use the drops after the expiry date (marked 'EXP') on the bottle and the box.

**If you have any other questions about your medicines you should ask a doctor or pharmacist.**

This leaflet was last approved on XXXXX

## **FURTHER INFORMATION**

*For any information about these drops, please contact your local Alcon office.*

### **België/Belgique/Belgien**

#### **Luxembourg/Luxemburg**

SA Alcon-Couvreur NV

Tel: + 32 (0)3 890 27 11 (België/Belgique/Belgien)

### **Lietuva**

Alcon Services Ltd. atstovybė

Tel: + 370 5 2 314 756

### **България**

Алкон България ЕООД

Tel: + 359 2 950 15 65

### **Magyarország**

Alcon Hungary Pharmaceuticals Trading Ltd

Tel: + 36-1-463-9080

### **Česká republika**

Alcon Pharmaceuticals (Czech Republic) s.r.o.

Tel: + 420 225 377 300

### **Nederland**

Alcon Nederland BV

Tel: + 31 (0) 183 654321

### **Danmark**

Alcon Danmark A/S

Tel: + 45 3636 3434

### **Norge**

Alcon Norge AS

Tel: + 47 67 81 79 00

### **Deutschland**

Alcon Pharma GmbH

Tel: + 49 (0)761 1304-0

### **Österreich**

Alcon Ophthalmika GmbH

Tel: + 43 (0)1 596 69 70

### **Ελλάδα**

#### **Κύπρος**

Αλκον Λαμποράτορις Ελλάς ΑΕΒΕ

Tel: + 30 210 68 00 811 (Ελλάδα)

### **Polska**

Alcon Polska Sp. z o.o.

Tel: + 48 22 820 3450

### **Eesti**

Alcon Eesti

Tel: + 372 6262 170

### **Portugal**

Alcon Portugal – Produtos e Equipamentos

Oftalmológicos, Lda.

Tel: + 351 214 400 330

### **España**

Alcon Cusí, S.A.

Tel: + 34 93 497 7000

### **România**

Alcon Pharmaceuticals Ltd.

Tel.: + 40 21 203 93 24

### **France**

Laboratoires Alcon

Tel: + 33 (0)1 47 10 47 10

### **Slovenija**

Alcon Pharmaceuticals, Podružnica v Ljubljani

Tel: + 386 1 422 5280

### **Ireland/Malta/United Kingdom**

Alcon Laboratories (UK) Ltd.

Tel: + 44 (0) 1442 34 1234 (United Kingdom)

### **Slovenská Republika**

Alcon Pharmaceuticals Ltd – oz

Tel: + 421 2 5441 0378

### **Ísland**

K. Pétursson ehf.

Tel: + 354 – 567 3730

### **Suomi/Finland**

Alcon Finland Oy

Tel: + 358 (0)9 8520 2260

**Italia**

Alcon Italia S.p.A.  
Tel: + 39 02 81803.1

**Sverige**

Alcon Sverige AB  
Tel: + 46 (0)8 634 40 00  
E-post: [receptionen@alconlabs.com](mailto:receptionen@alconlabs.com)

**Latvija**

Alcon Pharmaceuticals Ltd  
Tel: + 371 7 321 121